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an Low-Density Lipoprotein Be Too Low?
he Safety and Efficacy of Achieving Very Low
ow-Density Lipoprotein With Intensive Statin Therapy
PROVE IT-TIMI 22 Substudy
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avid A. Morrow, MD, MPH, FACC,*† Kausik K. Ray, MD,† Marc A. Pfeffer, MD, PHD, FACC,*
ugene Braunwald, MD, MACC,*† for the PROVE IT-TIMI 22 Investigators
oston, Massachusetts
OBJECTIVES This study sought to evaluate the safety and efficacy of achieving very low calculated
low-density lipoprotein (LDL) levels with intensive statin therapy.
BACKGROUND Intensive statin therapy reduces clinical events occurring after acute coronary syndrome
(ACS) and may result in LDL levels markedly lower than guideline levels. Prior epidemio-
logic and preclinical studies raise concerns about the safety of very low cholesterol levels.
METHODS The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myo-
cardial Infarction 22 (PROVE IT-TIMI 22) study compared intensive therapy (atorvastatin,
80 mg) and moderate therapy (pravastatin, 40 mg) in patients after ACS. Patients treated
with atorvastatin were divided by four-month LDL values into groups: 100, 80 to 100
(reference-range-meeting guidelines), 60 to 80, 40 to 60, and 40 mg/dl. Baseline,
clinical, and safety data were compared among groups achieving guideline recommendation
levels or lower.
RESULTS Among 1,825 patients with four-month LDL, 91% were at goal (100 mg/dl). The
distribution was 80 to 100 mg/dl (14%), 60 to 80 mg/dl (31%), 40 to 60 mg/dl (34%),
and 40 mg/dl (11%). Those with lower LDL levels were more often male, older, and
diabetic, and had lower baseline LDL levels. They had prior statin therapy and fewer prior
myocardial infarctions (MI). There were no significant differences in safety parameters,
including muscle, liver, or retinal abnormalities, intracranial hemorrhage, or death, in the very
low LDL groups. The 40 mg/dl and 40 to 60 mg/dl groups had fewer major cardiac events
(death, MI, stroke, recurrent ischemia, revascularization).
CONCLUSIONS Compared with patients treated with an accepted LDL goal (80 to 100 mg/dl), there was no
adverse effect on safety with lower achieved LDL levels, and apparent improved clinical
efficacy. These data identify no intrinsic safety concern of achieving low LDL and, therefore,
a strategy of intensive treatment need not be altered in patients achieving very low LDL
levels. (J Am Coll Cardiol 2005;46:1411–6) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.064Cardiology Foundation
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rhe 3-hydroxy-3-methyl glutaryl coenzyme A reductase
nhibitors (statins) have been shown consistently to reduce
ardiovascular events in patients with elevated cholesterol
evels. These benefits have been observed in major primary
revention (1–3) and secondary prevention trials (2–5) in
table patients with progressively lower baseline cholesterol
evels. Indications for the use of statins have been extended
o patients with cholesterol levels previously considered to
e normal (3,6–8). The Heart Protection Study showed a
enefit of treatment with simvastatin compared with pla-
ebo regardless of baseline cholesterol level in high-risk
atients (3). Treatment benefit was observed in patients
From the *Cardiovascular Division, Brigham and Women’s Hospital, and †The
IMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital,
oston, Massachusetts. The PROVE IT–TIMI 22 study was funded by Bristol-
yers Squibb. The A to Z trial was funded by Merck.s
Manuscript received January 27, 2005; revised manuscript received March 28,
005, accepted April 4, 2005.ho had baseline calculated low-density lipoprotein (LDL)
100 mg/dl, the target of therapy in a similar population at
he time of the study (6). Recent data have extended these
bservations to the early time period after acute coronary
yndromes (ACS) (9–11). The Pravastatin or Atorvastatin
valuation and Infection Therapy–Thrombolysis in Myo-
ardial Infarction 22 (PROVE IT-TIMI 22) trial showed
hat intensive therapy (atorvastatin, 80 mg) that achieved a
edian LDL level of 62 mg/dl was superior to standard
herapy (pravastatin, 40 mg) that achieved a median LDL
evel of 95 mg/dl after ACS in reducing clinical events (11).
However, intensive cholesterol lowering may not be
ithout risk. Cholesterol serves important physiologic roles
s a component of cell membranes and in vitamin synthesis.
reating patients with average or below average cholesterol
evels with high doses of potent statins can be expected to
esult in many patients achieving LDL cholesterol levels
ignificantly below target levels (6–8) (60 mg/dl). Pre-
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Can LDL Be Too Low? October 18, 2005:1411–6linical and epidemiologic data have raised some concerns
bout very low lipid levels. Early animal data with statins
howed increased rates of retinal and optic neuronal degen-
ration (12,13), and some epidemiologic studies have sug-
ested a relationship between low cholesterol levels, total
ortality, and intracranial hemorrhage (14–16). These
tudies have not defined causality, and reflect that low
holesterol levels may be the result of systemic illness, not
he cause of it. Nonetheless, concern remains that pharma-
ologically lowering cholesterol well beyond current targets
ay be harmful. The most common severe side effects of
tatins, muscle and liver toxicity, seem to be agent- and
ose-related (17). Although increasing doses of statins
esult in lower LDL levels, no definitive relationship be-
ween achieved LDL level and side effects has been noted.
urther, clinicians responding to recent trials have voiced
oncerns about the safety of very low LDL levels after
ntensive statin therapy.
To assess the safety and efficacy of achieving very low
DL levels after ACS, we analyzed the outcomes of
atients in the PROVE IT-TIMI 22 trial treated with
ntensive statin therapy.
ETHODS
he PROVE IT-TIMI 22 study was a randomized con-
rolled trial of intensive versus moderate cholesterol lower-
ng with statins and infection therapy with gatifloxacin
ersus placebo in patients stabilized from an ACS (18).
atients were enrolled within 10 days of presentation for
cute myocardial infarction (MI) or non–ST-segment ele-
ation ACS after stabilization (including revascularization if
lanned). Patients with ACS were eligible if total choles-
erol was 240 mg/dl (or 200 mg/dl if already treated
ith cholesterol-lowering therapy including statins). Pa-
ients were randomized to intensive therapy (atorvastatin,
0 mg) or standard therapy (pravastatin, 40 mg). A second
andomization of therapy with gatifloxacin versus placebo
as performed concurrently. Patients were followed up for a
ean of two years. The primary composite end point of
eath, MI, stroke, revascularization and unstable angina
equiring hospital admission was reduced by 16% (p 
.005) in the intensive therapy arm. No difference was seen
n the gatifloxacin versus placebo comparison (19). End
Abbreviations and Acronyms
ACS  acute coronary syndrome
LDL  low-density lipoprotein
MI  myocardial infarction
PROVE IT-TIMI 22  Pravastatin or Atorvastatin
Evaluation and Infection
Therapy–Thrombolysis In
Myocardial Infarction 22
ULN  upper limit of normaloints were adjudicated by an independent clinical events (ommittee. Definitions of trial end points were described
reviously (11).
The purpose of the present analysis was to examine the
afety and clinical outcomes of patients achieving very low
evels of cholesterol. Therefore the primary analyses were
estricted to the intensive treatment arm, because these
atients were far more likely to achieve such LDL levels
60 mg/dl). In addition, limiting the analysis to the
ntensive treatment arm removed any effect of the interac-
ion between lipid level achieved and the specific statin to
hich the patient was randomized. Further, patients who
id not achieve guideline-based recommendations (100
g/dl) were excluded from this analysis, because there is a
onsensus that LDL lowering beyond this point is war-
anted. Subjects were divided into subgroups by achieved
ipid levels at four months (80 to 100, 60 to 80, 40 to
0, and 40 mg/dl), a time at which it would be expected
hat lipid levels would have become stable from treatment
nd recovery from ACS and its sequelae.
Kaplan-Meier event rates (rates estimated from Kaplan-
eier curves at two years) for efficacy end points, including
he primary end point of the trial and its components, death,
I, and total stroke, were determined by four-month LDL
evel. Hazard ratios were calculated using the 80- to
00-mg/dl LDL group as the referent because these pa-
ients achieved cholesterol goals and did not achieve very
ow cholesterol levels. Comparisons were made using the
hi-square test for trend, and p values for trend are reported
nless otherwise stated. Kaplan-Meier estimates are com-
ared using the log-rank test. For the primary efficacy
omposite end point, multivariable analysis was performed
ccounting for differences in baseline characteristics among
chieved lipid groups (age, gender, diabetes, prior history of
I, baseline LDL levels, and smoking status). Crude
unadjusted) rates of safety measures were reported by
ubgroup, including hemorrhagic stroke, liver-related events
alanine aminotransferase 3 the upper limit of normal
ULN) and/or discontinuation of study drug for liver
unction abnormalities), muscle-related events (myopathy,
yositis creatine kinase 3 ULN, creatine kinase 10
LN without concurrent MI, and rhabdomyolysis) (17),
etinal adverse events (any event from the adverse event
atabase that mapped to a preferred term abnormality,
etina, and trauma/suicide.
ESULTS
tudy population and baseline characteristics. In the
ROVE IT-TIMI 22 trial, a total of 4,162 patients were
nrolled, and 2,099 were randomized to the intensive
reatment arm. Of these patients, 1,949 (92.9%) had four-
onth LDL levels checked. The distribution of four-month
DL levels in the intensive treatment group is shown in
igure 1. Of the patients who had four-month LDL levels
hecked, 193 (9.9%) had LDL 100 mg/dl; 1,756 patients
90.1%) met guideline treatment goals of LDL 100
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October 18, 2005:1411–6 Can LDL Be Too Low?g/dl. When the latter group was divided by achieved LDL
nto four groups for analysis, LDL levels were 80 to 100
g/dl in 256 (13.9%), 60 to 80 mg/dl in 576 (31.4%),
40 to 60 mg/dl in 631 (34.4%), and 40 mg/dl in 193
10.5%).
Baseline characteristics by treatment group are shown in
able 1. Patients who reached lower LDL levels were more
ikely to be older, male, and diabetic. Those who reached
ower LDL levels were less likely to have had a prior MI or
prior coronary artery bypass graft, to be a cigarette smoker,
r to have been on a statin before study initiation. Those
chieving lower LDL levels had lower baseline total cho-
esterol and LDL levels (with the four groups having a
edian LDL of 118, 112, 103, and 91 mg/dl in order of
escending achieved LDL level). Despite lower baseline
DL and total cholesterol levels, baseline high-density
ipoprotein and triglyceride levels did not differ between
roups. The percent reduction in LDL was progressively
reater in the groups that achieved lower LDL levels
anging from 23.9% to 62.5% (Table 1).
igure 1. Distribution of four-month calculated low-density lipoprotein
LDL) (mg/dl) levels among subjects treated with intensive statin therapy
atorvastatin, 80 mg).
able 1. Baseline Characteristics
Characteristic
A
>80–100
n  256
emographics
Age, median yrs 55 (49, 63) 5
Female 24
White 89
Diabetes 16
Hypertension 52
Prior MI 25
Prior CABG 16
Prior cerebrovascular disease 9
Smoker 44
Prior statin use, 2 weeks 38
BMI, median 29 (26, 33) 2
ipids, baseline
Total cholesterol, median 190 (168, 213) 18
LDL cholesterol, median 115 (94, 137) 11
HDL cholesterol, median 38 (32, 45) 3
Triglycerides, median 160 (116, 217) 15alues in parentheses are interquartile range.
BMI  body mass index; CABG  coronary artery bypass graft; HDL  high-densitafety results. Muscle side effects were infrequent (Table
), with no episodes of rhabdomyolysis observed. There did
ot seem to be any relationship between achieved LDL level
nd the development of muscle side effects. Similar results
ere observed for liver-related side effects, with no relation-
hip between achieved LDL and the frequency of either
iver enzyme elevations or discontinuation for abnormal
iver enzyme levels (Table 2). Similarly, there was no
ignificant association between the frequency of adverse
phthalmologic events (Table 2) and achieved LDL level.
here was one suicide in the intensive therapy arm
achieved LDL 100 mg/dl) and no traumatic deaths.
There was no difference in total strokes (Table 2). A small
umber of cerebral hemorrhages was seen in this cohort,
ne in the 80 to 100 mg/dl group (0.4%), and none
bserved in patients with achieved LDL 60 mg/dl (p 
.12). Aspirin was taken by 95% of subjects at the four-
onth visit, including the subjects with intracranial hem-
rrhage. Aspirin use did not differ among achieved LDL
roups. Subjects who did not have an LDL 100 mg/dl at
our months were more likely to have discontinued the study
rug, including for adverse events. Not surprisingly, more
atients who had adverse events and were off of the study
rug did not achieve the LDL goals. Beyond four months,
owever, the group of patients who at four months had
DL100 mg/dl had similar safety features compared with
hose who achieved lower LDL levels.
fficacy results. When the primary end point of the trial
as examined, there was a trend toward lower rates in the
escending achieved LDL groups (26.1%, 22.2%, 20.4%,
nd 20.4%, respectively, ptrend  0.1.) with the lowest rates
n the 40 to 60 mg/dl group and the 40 mg/dl group. A
ultivariable analysis was performed accounting for baseline
ifferences and showed that both of the lowest LDL groups,
ed LDL Cholesterol (mg/dl)
p Value
–80
576
>40–60
n  631
<40
n  193
65) 58 (52, 66) 59 (51, 69) 0.0006
17 16 0.008
93 89 0.11
17 25 0.04
49 49 0.88
15 17 0.008
10 10 0.025
4 7 0.07
31 23 0.001
24 15 0.001
32) 29 (26, 32) 29 (25, 33) 0.39
, 209) 176 (158, 193) 162 (144, 185) 0.0001
131) 100 (85, 119) 89 (71, 106) 0.0001
46) 37 (32, 45) 39 (33, 46) 0.47
, 208) 159 (123, 219) 161 (117, 218) 0.39chiev
>60
n 
6 (50,
24
93
16
50
16
10
5
39
25
9 (26,
2 (161
0 (93,
9 (32,
6 (117y lipoprotein; LDL  low-density lipoprotein; MI  myocardial infarction.
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Can LDL Be Too Low? October 18, 2005:1411–640 to 60 (hazard ratio  0.67 [95% confidence interval
.50 to 0.92]) and 40 (hazard ratio 0.61 [95% confidence
nterval 0.40 to 0.91]) showed significantly lower end point
ates than the referent group (Fig. 2).
When the individual components of the primary end
oint were examined (Table 2), there was no apparent effect
f achieved LDL on total mortality (p  0.8), however, MI
ended to be lower with lower LDL levels (p  0.01).
ISCUSSION
n this analysis performed among the intensively treated
atients in the PROVE IT-TIMI 22 trial, there seemed to
e a lower rate of clinical events and no increase in adverse
vents in patients who achieved very low cholesterol levels.
Table 2. Major Safety and Efficacy Outcomes
Safety Measure
>8
n
Muscle side effects*
Myalgia
Myositis
CK 3 ULN
CK 10 ULN
Rhabdomyolysis
Liver side effects
ALT 3 ULN
Study drug discontinued because of LFT
Other
Hemorrhagic stroke
Retinal AE
Suicide/trauma death
Study drug discontinued because of any AE
Major efficacy measures
Death
CHD death
Myocardial infarction
Any stroke
Primary composite*
*Primary composite  percent of subjects with any of the
requiring rehospitalization, and revascularization. Myalgia
symptoms with CK elevation; rhabdomyolysismuscle symp
AE  adverse event; ALT  alanine aminotransferase; C
function test; LDL  low-density lipoprotein; ULN  upp
igure 2. Hazard ratio of the primary end point compared with achieved
alculated low-density lipoprotein (LDL) 80 to 100 mg/dl (adjusted fort
ge, gender, baseline calculated low-density lipoprotein, diabetes mellitus,
nd prior myocardial infarction).he results of recent lipid-lowering trials in ACS suggest a
aradigm shift in the management of lipids in high-risk
atients (8,20); an appropriate strategy in high-risk patients
ay be to commence therapy with a high dose of a potent
tatin, monitor for side effects, and reduce the dose when
ide effects are seen. This is in contrast to previous strategies
f starting with a low dose and titrating upward to achieve
specific goal. This strategy resulted in a majority of
atients achieving LDL levels well below current guidelines.
linical features that predicted lower achieved LDL levels
ncluded lower baseline LDL, older age, male gender,
iabetes, and the absence of prior statin therapy.
afety. In patients treated with intensive lipid-lowering
herapy, there did not seem to be a relationship between
chieved LDL levels and the likelihood of adverse safety
vents. There were no trends toward increases in the rates of
xpected side effects such as myopathy or elevations in liver
nzyme levels based on achieved LDL levels. Rates of
nticipated adverse events such as elevations in liver and
uscle enzymes seen in the PROVE IT-TIMI 22 trial are
onsistent with previous data (21). In addition to the
xamination of rates of anticipated side effects, there was no
ncrease in all-cause mortality, intracranial hemorrhage,
phthalmologic side effects, or trauma/suicide with lower
chieved LDL levels, as had been suggested by previous
pidemiological data in non–statin-treated patients (14–16).
Statins have been extensively studied, and the side effect
rofile is well characterized. However, specific statins and
ent of Subjects)
hieved LDL Cholesterol (mg/dl)
p Trend
0
6
>60–80
n  576
>40–60
n  631
<40
n  193
4.3 6.2 5.7 0.75
0.6 0.6 0 0.64
0.7 1.9 1.0 0.18
0 0.3 0 0.45
0 0 0 1.0
3.0 3.2 2.6 0.98
2.6 2.4 1.6 0.83
0.2 0 0 0.12
0.9 1.0 0 0.48
0 0 0 1.0
9.4 9.7 9.8 0.99
1.4 1.3 0.5 0.59
0.5 0.6 0.0 0.06
0.7 0.5 0.6 0.009
0.9 0.6 1.6 0.32
22.2 20.4 20.4 0.10
ing: death, myocardial infarction, stroke, unstable angina
scle symptoms without CK elevation; myositis  muscle
ith CK10 ULN and evidence of renal dysfunction (17).
coronary heart disease; CK  creatine kinase; LFT  liver
it of normal.(Perc
Ac
0–10
 25
6.4
0.4
2.3
0
0
3.2
2.0
0.4
0.4
0
10.2
1.1
0.5
1.0
0.8
26.1
follow
 mu
toms whe class of drugs have not been without important side
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October 18, 2005:1411–6 Can LDL Be Too Low?ffects, including rhabdomyolysis and renal failure (22,23).
revious data suggest that the incidence of expected side
ffects such as myopathy and elevation of liver enzyme levels
ith statins is related to the specific statin and its dose, as
ell as to concomitant medications and illnesses (17,24). A
reviously published report of more than 100,000 person-
ears of treatment with pravastatin from the prospective
ravastatin Pooling Project (PPP), however, showed a
emarkable safety profile in the controlled and monitored
etting of clinical trials; the incidence of adverse effects was
imilar in pravastatin-treated and placebo-treated patients
25). The largest previously published experience, with 80
g of atorvastatin in 2,345 patients in multiple combined
rials with shorter-term follow-up (21), showed an excellent
afety profile. In the PROVE IT-TIMI 22 trial, both
reatment arms had favorable side effect profiles similar to
hose observed previously, but overall there were similar
ates of muscle side effects and a higher rate of elevations in
iver enzyme levels among patients treated with intensive
ipid lowering with atorvastatin 80 mg compared with
tandard lipid-lowering therapy with pravastatin 40 mg (11).
The present analysis extends the observations regarding
he safety of intensive statin therapy in several important
ays. This is the largest long-term specific study of the
afety of high-dose atorvastatin published to date. The study
as performed in a post-ACS population with multiple
oncomitant medications and comorbidities; these patients
ould be expected to be at high risk for adverse events.
owever, despite this risk profile, low rates of severe adverse
vents were noted. The observation that patients who
chieved very low LDL levels (60 mg/dl) did not have an
xcess of complications provides evidence that when using
igh-dose statins, an achieved LDL level below goal levels
s not associated with increased risks and therefore need not
e a reason for dose reduction. These findings are consistent
ith previous pooled data from multiple trials showing no
xcess risk of adverse events for patients achieving choles-
erol levels below 80 mg/dl with a range of doses of
torvastatin (26), but extends the range down to below even
0 mg/dl.
fficacy. In this analysis, patients treated with intensive
tatin therapy who achieved very low LDL levels had fewer
ardiovascular events than patients who achieved levels
earer to previous guideline recommendations (80 to 100
g/dl). This supports a “lower is better” hypothesis, but
oes beyond even what was seen in the PROVE IT-TIMI
2 trial, which showed a benefit of intensive therapy (with
median LDL of 62 mg/dl) compared with standard
herapy (with a median LDL of 95) (11). It suggests the
ossibility that further LDL lowering beyond the new
uideline optimal goal of 70 mg/dl (8) may translate into
n additional clinical benefit.
This benefit is consistent with the results of several other
rials. The Treating to New Targets (TNT) trial showed
ewer major adverse cardiac events in stable patients treated
ith 80 mg of atorvastatin compared with 10 mg of rtorvastatin daily, the first to show such a benefit with a
ingle agent (27). The Heart Protection Study showed a
enefit with statin therapy for the lowering of cholesterol
rom any baseline, including in those patients with baseline
evels 100 mg/dl (3). The Z phase of the Aggrastat to
ocor (A to Z) trial showed no significant benefit for early
ntensive simvastatin therapy (40 followed by 80 mg) versus
elayed standard simvastatin therapy (placebo followed by
0 mg). However, a significant reduction in events after six
onths was seen with resultant LDL levels of 66 mg/dl
ompared with 81 mg/dl (10). Extrapolation from previous
rials and epidemiologic data suggests that there may be a
inear or log-linear relationship of achieved LDL levels with
rotection from cardiovascular events and that benefit may
xtend to lowering LDL beyond the resultant levels in
ecent trials (8,28). Furthermore, cholesterol levels are in the
ange of 30 to 70 mg/dl in healthy neonates and 50 to 75
g/dl in hunter/gatherer populations without evidence of
therosclerosis (28).
tudy limitations. This is a post-hoc analysis, and all
ypotheses based on the results should be considered
xploratory. Perhaps most importantly, the analyses are
eing performed using subgroups based on an achieved
arameter (LDL). This raises the concern that there may be
mportant differences in patients who achieve one LDL
evel compared with those who achieve another. We have
ttempted to exclude such confounding by performance of
ultivariable analysis; however, we cannot exclude the
ffects of either unmeasured or unidentified covariates. In
ddition, no inference can be made regarding safety end
oints not examined in this analysis.
It is also important to note that the absence of a
elationship of side effects with achieved LDL was in
atients treated with a single dose of a single statin. It
annot be excluded that the rate of side effects would
ncrease if physicians increase dosing of one agent, change
gents, or add additional cholesterol-lowering agents in an
ttempt to achieve a lower LDL goal. Finally, the numbers
f patients with major safety end points in the PROVE
T-TIMI 22 trial was low; therefore, a clinically meaningful
ifference could have been missed as a result of a lack of
tatistical power. However, this is the largest group of
atients after ACS achieving such low LDL levels in the
ublished literature of which we are aware.
ONCLUSIONS
hen treating patients with intensive lipid-lowering ther-
py (with atorvastatin, 80 mg daily) after ACS, there did not
eem to be a relationship between the achieved LDL level
nd the risk of complications from statin therapy over a
wo-year period. However, there were lower rates of cardio-
ascular events in those achieving these very low LDL
evels. Therefore, it is not necessary to reduce the dose of a
tatin based on resultant LDL levels well below guideline
ecommendations. Additional data are needed to determine
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Can LDL Be Too Low? October 18, 2005:1411–6hether tailoring drug therapy to specifically target very low
DL levels would be safe and beneficial in high-risk
atients.
eprint requests and correspondence: Dr. Stephen D. Wiviott,
IMI Study Group, 350 Longwood Avenue, 1st Floor, Boston,
assachusetts 02115. E-mail: swiviott@partners.org.
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